Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391909 · ClinicalTrials.gov registry record
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
A clinical trial, sponsored by Bavarian Nordic.
- Completed
- Registry status
- 855
- Enrollment target
NCT02391909: Completed study, sponsored by Bavarian Nordic.
NCT02391909 is a clinical trial that has completed, run by Bavarian Nordic. The registered enrollment target is 855 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02391909 has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- 855 participants
- Enrollment target
Study Summary
This is a multicenter (at travel clinics), phase 4 observational prospective cohort study in healthy adult male and female travelers for whom typhoid vaccination with Vivotif is recommended, as per standard practice.
Interventions
- BIOLOGICAL Vivotif
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 855 participants |
| Start Date | 2015-08-26 |
| Est. Completion | 2017-02-21 |
What the finished NCT02391909 record still lists
NCT02391909 is an observational study that tracks outcomes without assigning an intervention. The registered 855 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Vivotif is the first listed.
NCT02391909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02391909 about?
NCT02391909 is a clinical study titled "Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers". This is a multicenter (at travel clinics), phase 4 observational prospective cohort study in healthy adult male and female travelers for whom typhoid vaccination with Vivotif is recommended, as per standard practice.
What is the current status of trial NCT02391909?
This trial is currently completed. The enrollment target is 855 participants. The study started on 2015-08-26. Estimated completion is 2017-02-21.
What interventions are being tested in trial NCT02391909?
The interventions under investigation include: Vivotif (BIOLOGICAL).
Who is sponsoring clinical trial NCT02391909?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI